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Introduction 
The renin–angiotensin system plays an important role in 
the development and maintenance of hypertension and 
hypertensive heart disease.
1 
Angiotensin  II  (Ang  II)  as  a  major  component  of  the 
renin–angiotensin system is among the potent mediators 
of  vascular  contraction  and  remodeling  and  stimulates 
aldosterone secretion. Ang II plays an important role in 
the  pathophysiology  of  hypertension
2  and  promotes 
short- and long-term metabolic and functional changes 
mostly by activating the type 1 receptors (AT1) located 
at  smooth  muscle  cells  (VSMCs).
3,4  AT1  receptor  – 
coupled  G  –  proteins  activate  PLC  which  in  turn 
activates  IP3  and  DAG  leading  to  release  of  calcium 
from the sarcoplasmic reticulum.
5,6 
It  has  been  suggested  that  the  increased  intracellular 
calcium ([Ca
2+]i) activates chloride channels causing an 
efflux of chloride and subsequent depolarization of the 
cell  membrane  leading  to  opening  of  voltage  –  gated 
calcium channels.
6-9 
To  date,  many  orally  available  sartans  have  been 
developed and are used in the treatment of hypertension 
and  damages  associated  with  diabetes  or  vascular 
diseases  like  atherosclerosis.  In  particular  the  good 
properties of new nonpeptide Ang II antagonists such as 
losartan  have  stimulated  the  design  of  different 
congeners.
10Ang  II  receptor  blockers  have  proved  to 
lower blood pressure  more effectively
11 and they  have 
been  more  tolerable  than  other  classes  of 
antihypertensives.
12 
Organic  calcium  antagonists,  known  also  as  calcium 
channel blockers, are a chemically heterogeneous group 
of  drugs  which  antagonize  calcium–dependent  events 
with varying degrees of potency and specificity.
13 Many 
of  these  compounds  appear  to  exert  their 
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elements in an angiotensin receptor blocker (Telmisartan) with key structural elements in 
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antihypertensive  and  antianginal  actions  through 
inhibition  of  voltage–dependent  L–type  calcium 
channels in cardiovascular system.
14 
Since  1,4–dihydropiridine  (DHP)  calcium  channel 
blockers (CCBs) have greater vasodilator selectivity than 
non–DHP  CCBs
15a  large  number  of  them  has  been 
developed. 
Most  patients  with  hypertension  require  more  than  a 
single  antihypertensive  agent,  particularly  if  they  have 
comorbid diseases.
16 
Combination  therapy  of  hypertension  with  separate 
antihypertensives or a fixed-dose combination offers the 
potential  to  decrease  adverse  effects,  lower  blood 
pressure, and obtain target blood pressure more quickly 
with  equivalent  or  better  tolerability  than  higher-dose 
monotherapy.  
Antihypertensive  agents  by  different  mechanism  of 
action  may offset adverse reactions  from each other.
17 
Combination therapies of ARBs with CCB which acts 
through  L–type  calcium  channels  have  beneficial 
therapeutic  and  protective  effects  on  cardiovascular 
system.
18-21 
In  a  recent  study  It  has  been  suggested  that  the 
combination  of  olmesartan  and  azelnidipine  has 
advantages  over  the  combination  of  olmesartan  and  a 
thiazide  with  respect  to  avoiding  hyperuricemia, 
sympathetic  activation,  renin-angiotensin-aldosterone 
system stimulation, inflammation, oxidative stress, and 
increased  arterial  stiffness  in  patients  with  moderate 
hypertension.  These  properties  may  provide 
cardiovascular protection in addition to the hypotensive 
effect.
22 Fixed-dosed combination regimens consisting of 
a calcium channel blocker and an angiotensin II type 1 
receptor blocker represent a new addition to the available 
antihypertensive  treatment  options.
23  An 
antihypertensive  agent  with  both  ARB  with  CCB 
properties would be more advantageous than fixed-dosed 
combinations in saving costs, reducing complexities of 
drug  formulations  with  equivalent  or  improved 
compliance. 
Dialkyl  1,4  –  dihydro  –  2,6  –  dimethyl  –  4  -  [(2'  – 
carboxy biphenyl – 4 – yl)methyl] imidazol – 4 – el ] – 
3,5 – pyridindicarboxylate (DHPEE) is a new compound 
which  is  synthesized  by  merging  the  key  structural 
elements  in  an  ARB  (Telmisartan)  with  key  structural 
elements in 1,4 – dihydropyridine CCB (Nifedipine) in 
Medicinal Chemistry Department, School of Pharmacy, 
Tabriz University of Medical Sciences, Tabriz, Iran.
18 In 
this  study,  for  the  first  time,  we  examined  its  dual 
calcium  channel  blocking  and  AT1-antagonist  activity 
on rat isolated aorta (Scheme1). 
 
 
Scheme 1. Chemical structure of DHPEE 
 
Materials and Methods  
Functional studies 
Wistar rats from either gender weighting 250  – 300 g 
were  used.  Rats  were  anesthetized  with  sodium 
pentobarbital  (50  mg/kg)  intraperitoneally  and  the 
thoracic aorta was quickly removed, gently cleaned of 
adhering fat and connective tissues, taking care not to 
damage the endothelium and cut in rings. 
Ring  segments  (3-5  mm)  were  mounted  between  two 
stainless steel triangle wires in 10 ml organ bath filled 
with modified Krebs solution under passive tension of 2g 
for about 1 hour.  
The  Krebs  solution  had  the  following  composition 
(mM):  NaCl  118,  KCl  4.7,  CaCl2  2.5,  MgSO4  1.2, 
KH2PO4  1.17,  NaHCO3  20  and  glucose  11.  The  rings 
were maintained at 37°C and gassed with a 95 % O2 and 
5 % CO2 mixture (PH = 7.4). 
Changes  in  isometric  tension  were  recorded  on  a 
computer-assisted  data  acquisition  system 
(ADInstrument,  Power  Lab/4SP,  v  6.1.1)  with  force–
displacement transducers (LETICA, Spain) as previously 
reported.
24-26 
In all experiments after 1  hour of equilibration period 
aortic rings were challenged with KCl (80 mM) to assure 
the  good  contractile  condition  of  the  preparations. 
During  this  equilibration  period,  tissues  were  washed 
every 15 min with fresh Krebs solution.
26 
Evaluation of the vasorelaxant effect of DHPEE 
To evaluate the vasorelaxant effect of DHPEE, after 1 h 
equilibration,  aortic  rings  precontracted  using 
phenylephrine  (1  µM)  or  KCl  (80  mM)  and  once  the 
plateau was obtained, different concentration of  DHPEE 
(0.1-80 µM) was individually  added to organ- bath. The  
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  percentages of phenylephrine or KCl–induced relaxation 
of DHPEE were recorded after 40 min incubation. 
Effect of DHPEE on dose – response curves to CaCl2 
After 60 min equilibration period in the normal Krebs 
solution, the aortic rings were incubated for 30 min in 
Ca
2+ - free Krebs solution plus 0.1mM EDTA.  
After  adding  KCl  (60  mM),  dose–response  curve  to 
calcium was obtained on control. The same protocol was 
repeated  in  the  same  aortic  rings  after  washing  with 
treatment with DHPEE (0.01, 0.1 and 1µM) for 30 min 
or nifedipine (0.1 µM) for 20 min.
27,28 
 
Effect of DHPEE on dose – response curves to Ang II 
After 1 h equilibration period, different concentrations of 
Ang II (starting at 1 nM) were added to organ–bath in a 
single dose manner. After adding the latest concentration 
of Ang II, the aortic rings were washed and recovered to 
baseline.  The  same  protocol  was  repeated  after 
incubation  with  different  concentrations  of  DHPEE 
(0.001, 0.01 and 0.1µM) for 30 min or losartan (0.01 and 
0.1µM) for 15min.
29-31 
Drugs 
Chemicals  used  were:  Nifedipine  (Zahravi 
pharmaceuticals  Co,  Tabriz  –  Iran),  Losartan  (Daru–
Pakhsh  Pharmaceutical  Co,  Tehran  –  Iran)  DHPEE 
(Medicinal Chemistry Department, School of Pharmacy, 
Tabriz  University  of  Medical  Sciences)  and  Ang  II 
(Sigma, USA). 
Losartan and Ang II were dissolved in distilled water. 
Nifedipine  and  DHP–ethyl  ester  were  dissolved  in 
absolute ethanol. Final bath concentration of ethanol as 
vehicle was 0.1 % V/V without any significant effect on 
the CaCl2 and Ang II- induced contractions. All of the 
solutions were protected from light. 
All other reagents were of analytical grade and obtained 
from MerkKGaA 62471 Damstadt, Germany. 
 
Statistical analysis 
The EC50 of the drug required to produce 50% of the 
maximal  response  were  determined  by  computer–
assisted  interactive  nonlinear  regression  analysis 
(Microsoft Excel 2007). 
The  maximal  response  (Emax)  produced  by  CaCl2  and 
Ang  II  was  expressed  as  percentage  of  the  maximum 
response and those by DHPEE, nifedipine and losartan 
were  expressed  as  the  percentage  relaxation  of  the 
agonist–induced contraction. Data are presented as mean 
± standard error of the mean (SEM). 
Statistical  evaluations  were  performed  using  paired 
student's t- test. p< 0.05 was taken as significant. 
 
Results 
Effect  of  DHPEE  on  Phenylephrine  or  KCl  induced 
contractile responses 
The concentration ranges and drug – tissue contact time 
were  chosen  after  preliminary  experiments,  which  had 
shown  that  each  concentration  of  antagonist  tested 
produced maximal inhibition within the first 40 min of 
treatment.  DHP–ethyl  ester  reduced  KCl–induced 
contractile responses of aortic rings in a concentration–
dependant  manner  (0.01-40  µM).  Beyond  this 
concentration, the relaxation was reduced. This can be 
related  to  low  solubility  of  DHPEE  in  water  at  high 
concentrations.  Similarly,  DHPEE  reduced 
phenylephrine–induced  contractile  responses  in  aortic 
rings  in  a  concentration–dependent  manner,  but 
maximum  relaxation  to  DHPEE  in  of  KCl-contracted 
rings  (Emax  =72.08  %  ±  5.37,  EC50=5.76),  was 
significantly higher than the response in phenylephrine-
contracted tissues (Emax =46.3 % ± 3.29, EC50 = 6.88) 
(Figure 1). 
 
 
 
 
 
 
Figure 1. Vasorelaxant effect of DHPEE on rat thoracic aorta 
rings precontracted with A: KCl (80 mM) and B: Phenylephrine 
(1 µM). Data are expressed as Mean±SEM, n=6.  
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Effects of DHPEE on dose – response curve of CaCl2 
CaCl2 induced a concentration  – dependent contractile 
effect on K
+ - depolarized smooth muscle. Preincubation 
of the k
+-depolarized tissues with DHPEE or nifedipine 
resulted in a non parallel shift to the right of the calcium 
dose  response  curves  (Figure  2).  In  addition,  DHPEE 
induced  a  concentration–dependant  and  significant 
reduction in the maximal contraction to CaCl2 (Table 1). 
 
 
 
Figure  2.  The  inhibitory  action  of  A:  DHPEE  [  0(♦),  0.01(■), 
0.1(▲),  1(ӿ)µM]  and  B:  nifedipine  [0(♦),  0.1(■)  µM  ]  on  the 
contractile response of rat isolated aorta induced CaCl2 in Ca- 
free Krebs' solution. Data are expressed as Mean±SEM, n=6. 
 
Table 1. Inhibitory effects of DHPEE on the CaCl2 induced 
CaCl2 
  EC50(M)  EMax± SEM 
Control  2.02  100 
DHPEE 0.01µM  2.67  71.43± 7.06
 * 
DHPEE 0.1 µM  2.86  59.36± 6.59
 *** 
DHPEE 1 µM  2.34  40.34± 7.94
 *** 
Nifedipine 0.1 µM  4.68  24.73± 5.71
*** 
Emax  and  EC50  from  rat  thoracic  aorta  rings  concentration-
response  curve  to  CaCl2,  in  the  absence  and  presence  of 
DHPEE or nifedipine, n=6.   
(*: p<0.05, **: p<0.01, ***: p<0.001) 
 
Effect of DHPEE on dose–response curve of Ang II 
The effect of the different concentrations of DHPEE and 
losartan on Ang II–evoked contractile responses in rat 
aortic strips is shown in figure 3 and table 2. Increasing 
concentrations  of  DHPEE  and  0.1µM  of  losartan 
resulted in a progressive and significant reduction in the 
maximal response to Ang II. The maximal response to 
Ang II was not significantly changed by losartan 0.01 
µM. Preincubation with losartan (0.01µM) resulted in a 
parallel  right  ward  shift  of  the  concentration–response 
curve  of  Ang  II.  However,  the  rightward  shift  with 
DHPEE or higher concentration of losartan (0.1µM) was 
in nonparallel fashion. 
 
 
 
 
 
 
 
 
Figure 3. The inhibitory action of A: DHPEE [ 0(♦), 0.001(■), 
0.01(▲),0.1(ӿ)µM] and B: Losartan [0(♦), 0.01(■), 0.1(▲) µM ] 
on the contractile response of rat isolated aorta induced by Ang 
II. Data are expressed as Mean±SEM, n=6. 
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  Table  2.  Inhibitory  effects  of  DHPEE  on  the  Ang  II  induced 
contraction 
  Ang II   
     
  EC50(µM)  EMax± SEM 
Control  0.158  100 
Losartan 0.01 µM  0.258  89.58 ± 1.59 
Losartan 0.1 µM  0.303  47.8 ± 7.32
 ** 
DHPEE 0.001µM  0.143  55.48 ± 12.12
 ** 
DHPEE 0.01 µM  0.126  47.56 ± 5.36 
*** 
DHPEE 0.1µM  0.175  26.76 ± 3.2 
*** 
Emax and EC50 to Ang II contractile response in rat thoracic aorta 
rings, in the absence and presence of DHPEE or Losartan, n=6. 
(*: p<0.05, **: p<0.01, ***: p<0.001) 
 
 
Discussion 
The present study has demonstrated, for the first time, 
vasorelaxant effects of newly synthesized DHPEE and 
its  dual  mechanism  of  action.  This  study  showed  that 
DHPEE acts in aortic rings producing a concentration–
dependent depressant effect on KCl and Phenylephrine–
induced  contractions.  Our  experiments  showed  that 
preincubation with DHPEE could effectively antagonize, 
in  a  concentration-dependent  manner,  Ca
2+-induced 
contractions suggesting that DHPEE reduced Ca
2+ influx 
through  voltage-operated  Ca
2+  channels  in  the  isolated 
aortic smooth muscle. These observations are consistent 
with  reports  suggesting  that  other  similar  compounds 
may  act  as  a  calcium  antagonist  through  L-type  Ca
2+ 
channels.
10 Smooth muscle contracts in response to the 
activation  of  voltage–dependent  and  receptor–operated 
Ca
2+ channels.
32, 33 
Since  DHPEE  inhibitory  effects  was  similar  to  those 
elicited  by  Ca
2+  channel  blockers,  we  compared  its 
antagonist  effect  to  the  one  produced  by  nifedipine,  a 
known  selective  inhibitor  of  the  L-type  Ca
2+  channel 
blocker.  In  different  types  of  smooth  muscle,  Ca
2+ 
channel  blockers  strongly  inhibit  the  high  K
+-induced 
contraction by blocking L-type Ca
2+ channels. DHPEE, 
like nifedipine, inhibited high K
+-induced contraction in 
rat aortic smooth  muscle suggesting that it  may block 
voltage-dependent  Ca
2+  channels.  However,  influx  of 
Ca
2+ through L-type Ca
2+ channels activation is not the 
only  source  to  increase  intracellular  calcium 
concentration  in  smooth  muscle  cells;  it  might  be 
increased  due  to  Ca
2+  release  from  intracellular  stores 
and/or Ca
2+ influx through non-L-type Ca
2+ channels.
34, 
35In  the  present  study,  DHPEE  inhibited  either 
phenylephrine or KCl– induced contractions with more 
inhibitory  effect  on  KCl–evoked  contraction.  These 
observations  suggest that DHPEE might interfere  with 
both  voltage-dependent  and  receptor–operated  Ca
2+ 
channels  reducing  the  Ca
2+  influx  and  consequently, 
opposing  contraction.  It  has  been  reported  that 
contractions  induced  by  α1-adrenoceptor  are  less 
sensitive to Ca
2+ channel blockers than is the high K
+-
induced contraction.
36 
Our experiments showed that contractile responses of rat 
aortic rings  to CaCl2 in  Ca
2+- free  medium containing 
KCl were inhibited by DHPEE, suggesting that DHPEE 
reduced  Ca
2+  influx  through  voltage–operated  Ca
2+ 
channels in the isolated aortic smooth muscle (Figure 2). 
This effect was very similar to the effect of produced by 
nifedipine as a prototype of L-type Ca
2+ channel blocker. 
Taken  together,  it  seems  that  the  inhibitory  effect  of 
DHPEE  on  voltage–dependent  Ca
2+  channels  is  more 
potent than receptor–operated Ca
2+ channels (Figure 1). 
Dimethyl  4-[2-butyl-1-(2’-carboxy  biphenyl-4-yl) 
methylimidazol-4-yl]-1,  4-dihydro-2,  6-
dimethylpyridine-3, 5-dicarboxylate (5a), is synthesized 
by merging the structural key elements of nifedipine and 
losartan and is structurally very similar to DHPEE. It has 
been  shown  that  5a,  like  DHPEE,  inhibited  the 
maximum  contractile  response  to  CaCl2  in  rat  aortic 
rings  and  also,  this  effect  was  nearly  the  same  as 
nifedipine- induced effect.
10 
In Ca
2+  free solution, in addition to rightward shift  in 
concentration–response  curve  for  CaCl2,  DHPEE 
depressed  the  maximum  response  to  calcium,  which 
suggests blocking the voltage dependant Ca
2+ channels 
by  DHPEE  seems  insurmountable.  Nifedipine  in  a 
similar  profile  of  effect  reduced  the  maximum 
contractile response and also made a rightward shift in 
concentration–response curve of CaCl2. This finding is 
in accordance with the results of other similar studies.
13, 
28 
Another aspect examined in the present study was the 
inhibitory  effect  of  DHPEE  on  angiotensin  AT1–
receptors  at  aortic  smooth  muscle  tissue.  Stimulating 
AT1  receptors  in  vascular  smooth  muscle  by  Ang  II 
produces potent vasoconstrictor response by increasing 
intracellular calcium from two main pathways: 1-influx 
through voltage-dependent L-type calcium channels and 
2-  inositol  1,4,5-trisphosphate-mediated  calcium 
mobilization from intracellular sources.
37, 38 
Our experiments showed that contractile responses of rat 
aortic  rings  to  Ang  II  were  inhibited  by  DHPEE  or 
losartan  in  a  similar  pattern  (Figure  3).A  compound 
structurally very similar to DHPEE, Diethyl 4-[2-butyl-
1-(2’-carboxy biphenyl-4-yl) methylimidazol-4-yl]-1, 4-
dihydro-2,6-dimethylpyridine-3,5-dicarboxylate  (5b) 
was synthesized recently, by merging the structural key 
elements of nifedipine and losartan. It has been shown 
that 5b inhibited the contractile response to single dose  
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of  Ang  II  in  rat  aortic  ring.
10  These  results  are  in 
agreement with the results of our study. 
Results from a previous study indicate that only up to 
one-half  of  the  Ang  II-induced  constriction  in  renal 
blood vessels is mediated by voltage-dependent L-type 
calcium  channels  responsive  to  the  dihydropyridine, 
nifedipine.  Nifedipine  exerted  maximum  inhibition  by 
blocking  50%  of  the  peak  Ang  II  response.  The 
remaining 50% of the vasoconstriction elicited by Ang II 
was  mediated  by  inositol  1,4,5-trisphosphate  (IP3)-
mediated  calcium  mobilization  from  intracellular 
sources. Heparin or TMB-8 was employed to evaluate 
intracellular calcium  mobilization, and co-administered 
with  Ang  II.  Each  agent  produced  dose-dependent 
inhibition  of  up  to  50%  of  the  maximum 
vasoconstriction produced by Ang II. From these results 
it  has  been  concluded  that  two  distinct  mechanisms 
calcium  mobilization  and  calcium  entry  signaling 
pathways that are of equal importance are involved in 
Ang  II  activation  of  AT1  receptors  to  trigger 
vasoconstriction.
37 In a recent study in rat aortic smooth 
muscle the contribution of  L-type calcium channels in 
Ang II induced vasoconstriction has been estimated at 
maximum 50% and was evaluated by a high (20 µM) 
concentration of nifedipine.
38 
In the present study DHPEE caused a rightward shift in 
concentration–response  curve  of  Ang  II  which  shows, 
blocking  the  effects  of  Ang  II  is  competitive  and 
insurmountable , like telmisartan (a selective long acting 
AT1 – receptor blocker ).
39,40Then, we compared the Ang 
II  blocking  activity  of  DHPEE  with  losartan,  as  a 
selective  AT1–receptor  blocker.  Losartan  caused  a 
rightward shift in concentration–response curve of Ang 
II without significant reduction in maximal response to 
Ang  II,  which  shows  losartan  is  a  competitive  and 
surmountable  antagonist  of  AT1–receptors.
29  However, 
higher concentration of losartan, like DHPEE, reduced 
the  maximum  contractile  response  to  Ang  II.  Ang  II 
contracts  the  smooth  muscle  by  increasing  the  [Ca
2+]i 
through  different  ways.
21,37,38  DHPEE  inhibits  Ang  II-
induced  contraction.  The  question  is  how  it  can  be 
proved that this inhibitory effect is produced by blocking 
AT1 receptors and not blocking L-type calcium channels. 
It is obvious from figure 3 and table 2 that DHPEE could 
inhibit Ang II induced contraction much more than 50%, 
on the other hand the maximum participation of L-type 
calcium  channel  pathway  in  Ang  II-  induced 
vasoconstriction is 50%. In addition, DHPEE inhibitory 
effect  is  more  similar  to  losartan  effect;  however,  it 
seems more potent than losartan.  
These  results  may  suggest  that  DHPEE  make 
vasorelaxation at least by two mechanisms: 1) blocking 
L-type calcium channels and 2) blocking AT1 receptors 
in  aortic  vascular  smooth  muscle.  Complementary 
studies  including  receptor-  and  channel-bindings  will 
give more insight to the exact mechanism(s) of action of 
DHPEE  in  vascular  smooth  muscle  tissue.  The  dual 
mechanisms of DHPEE in rat aortic rings demonstrated 
in this study may prove particularly important in future 
vasorelaxing therapy in cardiovascular diseases. 
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